2. Protein Tyrosine Kinase/RTK
  3. VEGFR
  4. Bevacizumab

Bevacizumab  (Synonyms: 贝伐珠单抗; Anti-Human VEGF, Humanized Antibody)

目录号: HY-P9906 纯度: 98.30%
COA

摩尔计算器

Bevacizumab 是一种人源化的 IgG1 单克隆抗体，高亲和力且特异性地与所有 VEGF-A 结合。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CAS No. : 216974-75-3

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货 数量
1 mg ￥1600
In-stock
2 mg ￥2720
In-stock
5 mg ￥4900
In-stock
10 mg ￥7400
In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Bevacizumab:

Bevacizumab 相关抗体

Top Publications Citing Use of Products

查看 VEGFR 亚型特异性产品:

查看所有亚型
VEGFR1/Flt-1 VEGFR2/KDR/Flk-1 VEGFR3/Flt-4

  • 生物活性

  • 实验参考方法

  • 纯度 & 产品资料

  • 参考文献

生物活性

Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.

同型

Human IgG1 kappa
推荐同型对照抗体
种属

Humanized
IC50 & Target

VEGF[1]
体外研究
(In Vitro)

Bevacizumab, a humanized monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity, and inhibits its interaction with VEGFR-1 and VEGFR-2[1]. Experimental analysis shows that the EC50 of Bevacizumab to bind VEGF analyzed by ELISA is 0.18 μg/mL. Binding kinetics assays show similar results that Bevacizumab inhibits the VEGF-induced proliferation of HUVEC with an IC50 value of 0.047±0.0081 μg/mL[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Bevacizumab 相关抗体:
体内研究
(In Vivo)

It is demonstrated that the subconjunctival administration of FD006 and Bevacizumab can significantly inhibit CoNV in NaOH cauterized rats compared with the control group (p?[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
分子量

149 kDa(Average)

CAS 号
性状

液体

颜色

Colorless to light yellow

中文名称

贝伐珠单抗； 贝伐单抗
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG1 kappa
Biological Activity
  • Immobilized VEGF165 Protein, Human (HY-P7110A) can bind Bevacizumab. The EC50 for this effect is 5.34 ng/mL.
纯度 & 产品资料

纯度: ≥99.0%

COA (173 KB)

抗体抑制剂使用指南 (1152 KB)
参考文献
Cell Assay
[2]

Human umbilical vein endothelial cells (HUVECs) (1×104 cells/100 μL/well) are seeded in 96-well plates and cultured at 37 for 14 h with Endothelial Cell Medium. After low-serum starvation overnight, cells are treated with different concentrations of FD006 or Bevacizumab which are pre-incubated with 10 ng/mL VEGF for 30 minutes and incubated at 37, 5% CO2 for 72 hours. Then, 10 μL CCK8 is added to each well and incubated for another 4 hours. The absorbance is measured by spectrophotometer at 450 nm to determine the cell viability[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration
[2][3]

Rats[2]
After modeling, ninety rats are randomly divided into five groups (eighteen rats per group) and receive a subconjunctival injection with 0.05 mL per rat of (1) 0.9% NaCl, (2) solvent, (3) 25 mg/mL Bevacizumab and (4) 25 mg/mL FD006 in the superior temporal conjunctiva on the day after modeling. All chemical burns and treatments are performed by one investigator. The operator is blinded to the treatment group from which each cornea is derived. At postoperative days 3, 7, 14, 21 and 28, the eyes are harvested for further studies after the rats are sacrificed.
Mice[3]
Five-week-old Balb/cAnNCrlBR athymic (nu+/nu+) mice are injected into the fourth mammary fat pad with MDA-MB-468 cells (107 cells per mice) resuspended in 200 μL of Matrigel. Seven days after the tumor cell injection, tumor-bearing mice are randomly assigned (n=10 per group) to receive the following: NVP-LDE225 20 mg/kg per os every day for 4 weeks; Bevacizumab 5 mg/kg intravenously (i.v.), twice a week for 4 weeks. Tumor diameter is assessed with a vernier caliper, and tumor volume (cm3) is measured.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献

Bevacizumab 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Bevacizumab216974-75-3Anti-Human VEGF, Humanized Antibody贝伐珠单抗 贝伐单抗VEGFRVascular endothelial growth factor receptorInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
Bevacizumab
目录号：
HY-P9906
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z